Work

Supplementary Table S1 from Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

Year: 2023

Type: supplementary-materials

Abstract: Confirmed best overall response per irRECIST by baseline PD-L1 CPS of {greater than or equal to} 1, {greater than or equal to} 20, and {greater than or equal to} 50

DOI: 10.1158/1078-0432.22477470

Authors: Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo Fernandez, Danny Rischin, Ezra E.W. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Jonathan Cheng, Wendy Snyder, Lillian L. Siu

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361888871

Cites:

Cited by:

Related to: 10